Ottobock SE & Co

GER:OBCK · DE000BCK2223

Health Care Equipment & SuppliesMedium

360

Value43

Profit price32

EV / EBIT51

Price / Owner Earnings13

Cash yield56

Owner Earnings Yield42

Dividend Yield69

Sales & asset price42

Price/Sales64

EV / Gross Profit42

Price/Book20

Quality69

Returns on capital75

Return on Capital87

Cash Return on Capital40

Return on Equity97

Profit margins64

EBIT Margin67

Gross Profitability61

Cash backing67

Cash Conversion91

Accruals71

Owner Earnings Margin40

Growth59

Sales growth31

Profit growth88

Profit Growth85

Long-Term EPS Growth82

Owner Earnings Growth97

Reinvestment75

Price momentum27

Safety29

Debt load17

Debt serviceability32

Refinancing60

Debt Payback3

Liquidity60

Sentiment54

Analyst ratings48

Expectations trend68

Opinion Changes50

Price Target Upside86

Market mood1

Value Creation16/20strong value creator

Creates more value than its capital costs
Owner earnings growing
Owner earnings per share growing
Reinvests at strong returns
Solid earnings base

What this means

Ottobock SE & Co generates returns well above its cost of capital, the foundation of durable shareholder value.

Profile

CountryGermany

IndustryHealth Care Equipment & Supplies

SizeMedium

TypePublic Company

ExchangeXTRA

Employees2,577

Websitecorporate.ottobock.com

ISINDE000BCK2223

Last UpdateApr 2, 2026

Indices

CDAX (Germany)SDAX (Germany)TecDAX (Germany)

Themes

NeurologyInjection MoldingAssistive TechnologyBiomedical EngineeringOrthopaedicsHealth CareMedical Device

Description

Analysis

Quality compounder

Ottobock SE & Co. KGaA earns the quality_compounder label: good underlying economics priced fairly, with no obvious bargain or excess.

On valuation, the picture is expensive. The owner-earnings multiple stands at 77.8×; owner earnings: the cash an owner could take out each year. The implied growth embedded in that price is around 25% a year, against analyst forecasts of 17%. The gap between price and consensus is worth watching: demanding expectations.

Growth is moderate; the safety picture is stretched. The company scores 16/20 on our value-creation score: strong value creator.

Flags to be aware of: The financial cushion is thinner than comfortable. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250

2026

All-time high

Mar 2026

All-time low

Feb 2026

Average rank

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023

Price/Sales

—

Price/Earnings

—

Price/Book

—

Dividend Yield

—

Value (overall)

—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Ottobock SE & Co with its peers

Embla Medical

CPH:EMBLA

CountryIceland

IndustryHealth Care Equipment & Supplies

SizeMedium

Full Stock Analysis →

Pharming

AEX:PHARM

CountryNetherlands

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

SHL Telemedicine

SWX:SHLTN

CountryIsrael

IndustryHealth Care Providers & Services

SizeX-Small

Full Stock Analysis →

Kamada

NSQ:KMDA

CountryIsrael

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

InMode

NSQ:INMD

CountryIsrael

IndustryHealth Care Equipment & Supplies

SizeSmall

Full Stock Analysis →

Anbio Biotechnology

NMQ:NNNN

—

CountryGermany

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View

1 · Watch OutGood· 100

Value

1 · ExpensiveGood Value· 100

Quality

1 · Weak FundamentalsHigh Quality· 100

Growth

1 · Tough TimesHigh Growth· 100

Safety

1 · High LeverageWell-Financed· 100

Sentiment

1 · SkepticismPositive· 100

Learn More →